title: Physical therapy program for cervical dystonia: a study of 20 cases.
abstract: Botulinum toxin (BTX) is the best therapeutic option inpatients with cervical dystonia (CD), but physical therapy (PT) can be added to the treatment to achieve better results. Forty of our 70 patients with CD were en-rolled in a controlled open study. Subjects were divided into two groups: G1 (intervention group comprising patients receiving BTX and PT) and G2 (control group comprising patients receiving BTX only). Both groups were assessed using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) and the 36-Item Short-Form Health Survey (SF-36). On the TWSTRS, signiﬁcant improvements in disease severity were seen in G1 and G2 but signiﬁcant improvements on the pain and disability subscales were seen only in G1 patients.There was a signiﬁcant difference only on the pain sub-scale between G2 and G1 following treatment. An analysis of the physical aspects of SF-36 showed signiﬁcant improvement in G1 on three subscales. An intergroup difference was also seen on two subscales.Regarding emotional aspects, G1 showed a signiﬁcant improvement on three subscales. A signiﬁcant difference on two subscales was also seen between G2 and G1 following treatment. BTX plus PT treatment achieved symptom relief in patients with CD and improved their quality of life.
authors: Movement Disorders Clinic, Division of Neurology, Hospital das Clínicas, University São Paulo School of Medicine, São Paulo, Brazil. m_araujoribeiro@hotmail.com
authors: Mariana Araujo Ribeiro
authors: MA
authors: Queiroz
authors: Hsin Fen
authors: HF
authors: Chien
authors: Flávio Augusto
authors: FA
authors: Sekeff-Sallem
authors: Egberto Reis
authors: ER
authors: Barbosa
mesh_terms: D001905:Botulinum Toxins / Q000627:therapeutic use*; D001938:Brazil; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000209:etiology; D059408:Pain Management / Q000379:methods; D026741:Physical Therapy Modalities; D014103:Torticollis / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D001905:Botulinum Toxins
references: Physiother Theory Pract. 2008 Jul-Aug;24(4):275-90
references: 18574753
references: Mov Disord. 2004 Jun;19(6):681-7
references: 15197708
references: Arch Phys Med Rehabil. 2004 Mar;85(3 Suppl 1):S41-5
references: 15034854
references: Mov Disord. 2002 Jul;17(4):838-41
references: 12210891
references: Mov Disord. 2005 Jul;20(7):783-91
references: 15736159
references: Parkinsonism Relat Disord. 2010 Jan;16(1):8-11
references: 19589716
references: Arq Neuropsiquiatr. 2011;69(2B):316-9
references: 21625757
references: Arch Phys Med Rehabil. 2004 Oct;85(10):1684-8
references: 15468031
references: Neurology. 1993 Apr;43(4):834-6
references: 8469349
references: Funct Neurol. 2007 Apr-Jun;22(2):95-100
references: 17637212
references: J Neurol. 2002 Jul;249(7):842-6
references: 12140667
references: Eur J Neurol. 2007 Oct;14(10):1129-37
references: 17708754
references: Funct Neurol. 2003 Oct-Dec;18(4):219-25
references: 15055747
references: Brain Res Cogn Brain Res. 2002 May;13(3):313-22
references: 11918997
references: J Neurol Neurosurg Psychiatry. 2000 Nov;69(5):658-60
references: 11032623
references: Stroke. 2006 Jan;37(1):172-8
references: 16322492
references: Mov Disord. 1998 Nov;13(6):941-6
references: 9827619
references: N Engl J Med. 2006 Aug 24;355(8):818-29
references: 16928997
references: Acta Med Port. 2006 Jul-Aug;19(4):281-7
references: 17328844
references: Physiother Res Int. 2006 Jun;11(2):117-22
references: 16808092
references: Mov Disord. 2007 Feb 15;22(3):341-7
references: 17216640
references: Arq Neuropsiquiatr. 2011 Dec;69(6):900-4
references: 22297876
references: Mov Disord. 2006 Dec;21(12):2240-3
references: 17029278